Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aneczem** is a Farmaprim topical fixed-dose dermatologic combination containing betamethasone dipropionate, clotrimazole, and gentamicin sulfate. Betamethasone is a potent glucocorticoid that suppresses inflammation and pruritus; clotrimazole is an imidazole antifungal that inhibits fungal ergosterol synthesis; and gentamicin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis. The cream and ointment are marketed for corticosteroid-responsive dermatoses complicated by, or suspected to involve, secondary bacterial and/or fungal infection. ([farmaprim.md](https://www.farmaprim.md/en/products/aneczem-crema))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aneczem.